Last reviewed · How we verify
Placebo IM
Placebo IM is an inert substance administered by intramuscular injection that produces no pharmacological effect.
At a glance
| Generic name | Placebo IM |
|---|---|
| Also known as | Saline, Placebo |
| Sponsor | Alexza Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
As a placebo, it contains no active pharmaceutical ingredient and works through the placebo effect—the therapeutic benefit derived from patient expectation and the clinical context of treatment rather than any direct molecular mechanism. Placebo IM was developed by Alexza Pharmaceuticals as a delivery system for rapid-onset medications, though the placebo formulation itself has no intrinsic pharmacological activity.
Approved indications
Common side effects
Key clinical trials
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (PHASE3)
- BPL-1357 Against H1N1 Influenza Virus Challenge (PHASE2)
- A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (PHASE2)
- A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine (PHASE1)
- A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (PHASE3)
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (PHASE3)
- Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age (PHASE1, PHASE2)
- A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo IM CI brief — competitive landscape report
- Placebo IM updates RSS · CI watch RSS
- Alexza Pharmaceuticals, Inc. portfolio CI